Agência Brasil – The Butantan Institute today signed with the North American pharmaceutical group Merck Sharp and Dhome (MSD) a contract to prevent dengue fever in Brazil. technology transfer for the development and commercialization of the dengue vaccine abroad. The agreement provides for an initial payment of 25 million US dollars, making it the largest of its kind signed by the Brazilian pharmaceutical industry. The Butantan Institute could receive up to 101 million USD, which will be invested in the research and production of vaccines by the body, in conjunction with the State Secretariat for Health of São Paulo.
Non-repayable support of an amount of R $ 120 million. The National Bank for Economic and Social Development (BNDES) has authorized the Butantan Institute to develop the dengue vaccine phase 3 clinical research, that is to say, undergoing testing in humans. This is the last step before the application for registration. With funding from the bank, the institute has also developed an innovative freeze-drying process, with a patent issued in several countries around the world.
